ProCE Banner Activity

CME

CCO Independent Conference Highlights of the European Hematology Association 2022 Congress

Text Module

Review expert perspectives and insights on the most clinically important data presented at EHA 2022 for acute myeloid leukemia, chronic lymphocytic leukemia, follicular lymphoma, multiple myeloma, and Waldenström macroglobulinemia.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: September 06, 2022

Expiration: September 05, 2023

No longer available for credit.

Share

Faculty

Stéphane de Botton

Stéphane de Botton, MD

Associate Professor
Department of Clinical Hematology
Université Paris Saclay
Paris, France
Physician
Department of Hematology
Gustave Roussy
Villejuif, France

Jesús F. San-Miguel

Jesús F. San-Miguel, MD, PhD

Head, Hematology Department
Professor of Medicine
Hospital Universitario de Salamanca and Centro de Investigación del Cáncer
University of Salamanca
Salamanca, Spain

Alessandra Tedeschi

Alessandra Tedeschi, MD

Director of Indolent Lymphoproliferative Disorders
Department of Hematology
Niguarda Cancer Center
Niguarda Hospital
Milan, Italy

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

BeiGene, Ltd.

Jazz Pharmaceuticals Inc

Target Audience

This program is intended for physicians and other healthcare professionals who care for patients with hematologic malignancies.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate clinical trial data for hematologic malignancies and determine how they have an impact on evolving global clinical practice patterns, as well as how these data can be applied to personalize care and optimize patient outcomes
  • Assess the mechanisms of action of novel investigational agents being examined in patients with hematologic malignancies, including leukemia, lymphoma, multiple myeloma, myelodysplastic syndromes, and myeloproliferative neoplasms
  • Develop strategies to address treatment-related adverse events in patients who receive therapy for hematologic malignancies

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

Stéphane de Botton, MD

Associate Professor
Department of Clinical Hematology
Université Paris Saclay
Paris, France
Physician
Department of Hematology
Gustave Roussy
Villejuif, France

Stéphane De Botton, MD: consultant/advisor/speaker: AbbVie, Astellas, Bristol-Myers Squibb, Forma, Jazz, Servier, Syros.

Jesús F. San-Miguel, MD, PhD

Head, Hematology Department
Professor of Medicine
Hospital Universitario de Salamanca and Centro de Investigación del Cáncer
University of Salamanca
Salamanca, Spain

Jesús F. San-Miguel, MD, PhD:consultant: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Karyopharm, MSD, Novartis, Regeneron, Roche, SecuraBio, Sanofi, Takeda.

Alessandra Tedeschi, MD

Director of Indolent Lymphoproliferative Disorders
Department of Hematology
Niguarda Cancer Center
Niguarda Hospital
Milan, Italy

Alessandra Tedeschi, MD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeiGene, Janssen.

Staff Disclosure

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant financial relationships to disclose.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant financial relationships to disclose.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer: individual publicly traded stocks/stock options: AstraZeneca.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant financial relationships to disclose.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant financial relationships to disclose.

Kristen Rosenthal, PhD

Clinical Editor

Kristen Rosenthal, PhD, has no relevant financial relationships to disclose.

Justine Stanley, MSc

Editorial Contributor

Justine Stanley has no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from September 06, 2022, through September 05, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.

 

Goal


The goal of this activity is to improve global learners’ understanding of how to optimally apply recent practice-changing findings in the treatment of patients with hematologic malignancies.